New obesity drugs are posting surgical-scale weight-loss numbers. Is the gap closing, or are we mistaking early results for the final answer?
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) will be conducting a review of ...
Dr Daskalakis explains revisions to the government budget rules that could have long-term impacts on scientific funding.
In patients with ulcerative colitis exposed to anti-TNF therapy, tofacitinib is linked to higher rates of clinical and ...
Fear, withdrawal symptoms, and a lack of professional support are common barriers to detoxification from opioid substitution ...
Supplementation with vitamin K2 may help slow the progression of coronary artery calcification among people with mild ...
Qure may seek approval in the UK first while in talks with the FDA about its request for a larger, sham-controlled trial of ...
The EMA approves a new formulation of a levodopa-carbidopa combination to treat moderate-to-severe motor fluctuations in patients with Parkinson’s disease.
Prior authorization remains a major barrier to biologic access in AD. Dr Chuck Vega covers denial rates, appeal outcomes, and the clinical data that make the fight worthwhile.
Researchers report the 5-year survival outcomes with lisocabtagene maraleucel in heavily pretreated patients with relapsed or ...
The EMA says the benefits of Tavneos no longer outweigh the risks for the treatment of active granulomatosis with polyangiitis.
A single dose of the LSD-based therapy DT120 produced rapid antidepressant effects that remained significant through 12 weeks in a pivotal phase 3 trial of major depressive disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results